Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | PPID | Q08752 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878485 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTL3MBTL1MMP8PPID | |
| SCHEMBL30929593 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTL3MBTL1MMP8PPID | |
| Hydrochloric Acid SCHEMBL27723691 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTL3MBTL1MMP8PPID | |
| Hydrochloric Acid SCHEMBL27396543 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTL3MBTL1MMP8PPID | |
| SCHEMBL29176945 | 0.91 | ALDH1A1 (0.50) | SMN1; SMN2MAPTL3MBTL1EPHX2PPARG | |
| SCHEMBL5954392 | 0.88 | PPARG (0.56) | SMN1; SMN2MAPTL3MBTL1EPHX2PPARG | |
| SCHEMBL5954395 | 0.88 | PPARG (0.56) | SMN1; SMN2MAPTL3MBTL1EPHX2PPARG | |
| SCHEMBL29176922 | 0.87 | CD274 (0.49) | MMP8MEN1KMT2A | |
| SCHEMBL29176962 | 0.87 | SMN1; SMN2 (0.45) | SMN1; SMN2PPIDLMNAMEN1KMT2A | |
| SCHEMBL106075 | 0.86 | MAPT (0.67) | MAPTL3MBTL1SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114072486-B | Alkaline ashless additive and lubricating composition containing said additive | 路博润公司 | 2023-06-09 | — | — | CN | claimed |
| CN-114072486-A | Basic ashless additives and lubricating compositions containing said additives | 路博润公司 | 2022-02-18 | — | — | CN | claimed |
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4414365-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-115260180-B | Triazole condensed ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| CN-109843856-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2009026407-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2007034278-A2 | FUSED IMIDAZOLE DERIVATIVES AS C3A RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| EP-1492780-A1 | 5-SUBSTITUTED 1,1-DIOXO-[1,2,5]THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | Novartis AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-6784293-B1 | SOLUTION AND SOLID-PHASE SYNTHESIS OF BOC-PROTECTED 3-AMINOHYDANTOINS/THIOHYDANTOINS AND 3-AMINODIHYDROURACILS/ DIHYDROTHIOURACILS | THE PROCTER & GAMBLE COMPANY | 2004-08-31 | — | — | US | disclosed |
| WO-2003082841-A1 | 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
| WO-2001027087-A2 | PROCESS FOR MAKING BOC-PROTECTED 3-AMINOHYDANTOINS/THIOHYDANTOINS AND 3-AMINODIHYDROURACILS/DIHYDROTHIOURACILS | THE PROCTER & GAMBLE COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
| EP-0650487-A1 | NOVEL DIAZABICYCLOALKENES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994002479-A1 | NOVEL DIAZABICYCLOALKENES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1994-02-03 | — | — | WO | disclosed |
| US-4435322-A | Heterocyclic compounds containing an alkoxycarbonyl and a substituted methyl group | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SMN1; SMN2 4385/4885MAPT 3928/4885L3MBTL1 2112/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SMN1; SMN2 4385/4885MAPT 3928/4885L3MBTL1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.